Methods of treating ulcerative colitis
AssigneeSalix Pharmaceuticals, Inc.
InventorsWilliam Forbes, Enoch Bortey, Craig Paterson, Pam Golden
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of treating and inducing ulcerative colitis in a subject. Also provided are methods of treating subjects with mild to moderate active ulcerative colitis, including ulcerative proctitis and proctosigmoiditis. Also provided are methods of administering budesonide to a subject to treat ulcerative colitis, including ulcerative proctitis and proctosigmoiditis.
Claims58
A method of treating ulcerative colitis (UC) in a subject, comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide BID for two weeks, followed by 2 mg budesonide QD for four weeks.
A method of alleviating symptoms in a subject with ulcerative colitis, comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide BID for two weeks, followed by 2 mg budesonide QD for four weeks.
A method of treating ulcerative colitis, comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide BID for two weeks, followed by 2 mg budesonide QD for four weeks, wherein subjects experience a lower than expected systemic level of budesonide in the four weeks of QD dosing.
A method of inducing remission in subjects with active mild to moderate distal ulcerative colitis (UC) comprising, administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide twice daily (BID) for two weeks, followed by 2 mg budesonide once daily (QD) for four weeks.
A method of inducing remission in subjects with active mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide twice daily (BID) for two weeks, followed by 2 mg budesonide once daily (QD) for four weeks.
A method of inducing remission in a subject with ulcerative proctitis, comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide twice daily (BID) for two weeks, followed by 2 mg budesonide once daily (QD) for four weeks.
A method of inducing remission in a subject with ulcerative proctosigmoiditis, comprising administering a foam composition comprising budesonide to the subject, wherein the subject is administered 2 mg budesonide twice daily (BID) for two weeks, followed by 2 mg budesonide once daily (QD) for four weeks.
Dependencies are inferred from the claim text.